CKD Clinical Trial
Official title:
Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients
Assessment for usage of laxatives and probiotics ,and its role in improving uremic parameters of CKD as GFR, UREA ,CREATININE, CLINICAL and UREMIC assessment (lower limb edema ,UOP,base of chest ,vomiting ,dyspnea,blood pressure measurement)
with advanced CKD stages ,also have been linked to the high prevalence of constipation in CKD,Lactulose is a synthetic disaccharide.Lactulose is poorly absorbed from the gastrointestinal tract remains virtually unchanged and is then fermented by gut microbiota that increase osmotic effects and intraluminal gas formation . lactulose reduces the nitrogen products and urea, creatinine, uric acid, and b2- microglobulin levels. Lactulose also suppress tubulointerstitial fibrosis in a rat model of a kidney disease study . Lactulose modifies the gut microbiota, increasing the abundance of Bifidobacteria and Lactobacilli after 8 weeks of 30 ml lactulose syrup thrice daily, and ameliorates CKD progression by suppressing uremic toxin production .probiotics include vast array of products with living organisms whose purpose is to improve intestinal microbial balance and produce beneficial effect on ones health .probiotics is an alternative therapy for patients with CKD ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03277911 -
Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases
|
N/A | |
| Active, not recruiting |
NCT04008810 -
Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
|
||
| Completed |
NCT05144971 -
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
|
||
| Active, not recruiting |
NCT05356325 -
FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.
|
||
| Not yet recruiting |
NCT04491669 -
Screening of Gastrointestinal Tract Bleeding Causes Among Chronic Renal Failure Patients
|
||
| Completed |
NCT04709120 -
Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
|
||
| Terminated |
NCT03277183 -
Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin
|
Phase 4 | |
| Enrolling by invitation |
NCT04491227 -
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|
||
| Recruiting |
NCT06279429 -
Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia
|
N/A | |
| Recruiting |
NCT03501745 -
Smart-CKD/BP Study
|
N/A | |
| Recruiting |
NCT04708743 -
The Tongue Features Associated With Chronic Kidney Disease
|
||
| Completed |
NCT04119570 -
CKD Report Card Pilot Trial
|
N/A | |
| Completed |
NCT06374043 -
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
|
Phase 4 | |
| Not yet recruiting |
NCT06094920 -
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
|
Phase 4 | |
| Recruiting |
NCT04819217 -
Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease
|
N/A | |
| Completed |
NCT05970094 -
Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5
|
N/A | |
| Withdrawn |
NCT04782297 -
Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)
|
||
| Recruiting |
NCT05784389 -
Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5
|
N/A | |
| Recruiting |
NCT04630132 -
Renal Ageing-sarcopenia Network
|
||
| Not yet recruiting |
NCT06143098 -
Some Hematological Profile in Children With Chronic Kidney Disease
|